topic

521 Immune regulatory metabolites in human ovarian cancer
Julian Lum, Marisa Kilgour, Sarah MacPherson, Lauren Zacharias, Sarah Keyes, Bertrand Allard, Julian Smazynski, Peter Watson, John Stagg, Bradley Nelson, Ralph Deberardinis, Phineas Hamilton

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A319; DOI: 10.1136/jitc-2020-SITC2020.0521
523 A subset of mature neutrophils contains the strongest PMN-MDSC activity in blood and tissue of patients with head and neck cancer
Yu Si, Kirsten Bruderek, Simon Merz, Philip Jansen, Stephan Lang, Matthias Gunzer, Joachim Klode, Anthony Squire, Sven Brandau, Sven Brandau

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A320; DOI: 10.1136/jitc-2020-SITC2020.0523
530 T-cell immunoglobulin– and mucin domain–containing (TIM)–3 downregulation in response to ex vivo activation and cancer targets correlates to NK cell functionality
Tram Dao, Sandro Matosevic, Sagar Utturkar, Nadia Lanman

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A324; DOI: 10.1136/jitc-2020-SITC2020.0530
533 Cross-species immunogenomic analysis identifies pathways of canine natural killer cell response to cytokine therapy, and reveals convergence of activated dog and human natural killer transcriptomes
Alicia Gingrich, Taylor Reiter, Sean Judge, Daniel York, Mio Yanagisawa, Ian Sturgill, Rachel Brady, Kevin Stoffel, Arta Monjazeb, Robert Rebhun, C Titus Brown, Robert Canter

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A325; DOI: 10.1136/jitc-2020-SITC2020.0533
535 Electroporation of B cells is correlated with cell size change during B cell expansion
Jian Chen, George Sun

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A326; DOI: 10.1136/jitc-2020-SITC2020.0535
536 Divergent cancer etiologies drive distinct B cell signatures and tertiary lymphoid structures in head and neck cancer
Ayana Ruffin, Anthony Cillo, Tracy Tabib, Angen Liu, Sayali Onkar, Sheryl Kunning, Caleb Lampenfeld, Irina Abecassis, Zengbiao Qi, Ryan Soose, Umamaheswar Duvvuri, Seungwon Kim, Steffi Oesterrich, Robert Lafyatis, Robert Ferris, Dario Vignali, Tullia Bruno

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A326-A327; DOI: 10.1136/jitc-2020-SITC2020.0536
546 The differentiation status of systemic PD1+ CD8 T cells is associated with favorable outcome to PD1 blockade therapy in non small cell lung cancer
Asma Khanniche, Ying Wang

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A331; DOI: 10.1136/jitc-2020-SITC2020.0546
555 Inhibition of FOXP3 by stapled alpha-helical peptides alters Regulatory T Cell function
Katrina Hawley, Rachel Eclov, Marie Fefferman, Gregory Bird, Mathew Schnorenberg, Ravand Samaeekia, Loren Walensky, Matthew Tirrell, James LaBelle

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A336; DOI: 10.1136/jitc-2020-SITC2020.0555
559 Fostriecin potentiates genome instability and anti-tumor immunity in ovarian cancer
Remya Raja, Christopher Wu, Kristina Butler, Marion Curtis

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A337; DOI: 10.1136/jitc-2020-SITC2020.0559
561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation
Alexander Muik, Isil Altintas, Rachelle Kosoff, Friederike Gieseke, Kristina Schödel, Theodora Salcedo, Saskia Burm, Aras Toker, Lena Kranz, Mathias Vormehr, David Eisel, Mark Fereshteh, Özlem Türeci, Esther Breij, Tahamtan Ahmadi, Ugur Sahin, Maria Jure-Kunkel

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A338-A339; DOI: 10.1136/jitc-2020-SITC2020.0561

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages